Narsoplimab is a human monoclonal antibody that targets mannan-binding lectin-associated serine protease-2 (MASP-2), the effector enzyme of the lectin pathway of the complement system. Narsoplimab has the potential for the treatment of high-risk transplant-associated thrombotic microangiopathy.